Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Safety and Efficacy of RT002, an Injectable Botulinum Toxin Type A, for Treating Glabellar Lines

Results of a Phase 1/2, Open-Label, Sequential Dose-Escalation Study

Garcia-Murray, Enrique MD*; Velasco Villasenor, María Luisa MD; Acevedo, Berenice MD*; Luna, Silvia MD*; Lee, Jane BS; Waugh, Jacob M. MD; Hornfeldt, Carl S. PhD

doi: 10.1097/DSS.0000000000000276
Original Article

BACKGROUND RT002 is a new injectable BoNTA product. This formulation limits the spread of BoNTA, potentially permitting safe administration of larger doses and possibly extending its duration of action.

OBJECTIVE This phase 1/2 clinical study was designed to establish the safety of RT002 for the treatment of moderate-to-severe glabellar lines.

MATERIALS AND METHODS Subjects were randomized into four groups (N=12/group). Cohorts 1-3 received escalating doses of RT002 ranging from half the equivalent dose of approved toxins up to twice the current dose levels. The safety of each dose was confirmed prior to administering the next dose. Subjects in Cohort 4 were treated with the highest dose and observed for 36 weeks or until GLSS returned to baseline.

RESULTS All doses of RT002 were well-tolerated. Common AEs were headache and mild injection site reactions. At Week 4, all doses of RT002 were highly effective at maximum frown. Cohort 4 achieved 7 month median duration. At 6 months, 80% of subjects maintained a ≥1-point improvement in Investigator GLSS and 60% maintained WSS of None or Mild. Study limitations include an open-label design and modest number of subjects.

CONCLUSION RT002 is a safe and effective BoNTA product with an extended duration of action.

*Private Clinic, Alvaro Obregon, Mexico, D.F.;

Private Clinic, Colonia Roma, Mexico, D.F.;

Revance Therapeutics, Inc., Newark, California

Address correspondence and reprint requests to: Enrique Garcia-Murray, MD, Calzada Águilas No. 206-B, Col. Las Águilas, Del. Álvaro Obregón, C.P. 01710, México D.F., or e-mail:

Supported by Revance Therapeutics.

J. Lee, J. M. Waugh, and C. S. Hornfeldt are employees of Revance Therapeutics. The remaining authors have indicated no significant interest with commercial supporters.

© 2015 by the American Society for Dermatologic Surgery, Inc. Published by Lippincott Williams & Wilkins
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website